Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
6.00
-0.01 (-0.17%)
At close: Dec 23, 2025, 4:00 PM EST
5.99
-0.01 (-0.17%)
After-hours: Dec 23, 2025, 4:10 PM EST
Vir Biotechnology Employees
Vir Biotechnology had 408 employees as of December 31, 2024. The number of employees decreased by 179 or -30.49% compared to the previous year.
Employees
408
Change (1Y)
-179
Growth (1Y)
-30.49%
Revenue / Employee
$41,324
Profits / Employee
-$1,224,640
Market Cap
834.75M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 408 | -179 | -30.49% |
| Dec 31, 2023 | 587 | 11 | 1.91% |
| Dec 31, 2022 | 576 | 132 | 29.73% |
| Dec 31, 2021 | 444 | 117 | 35.78% |
| Dec 31, 2020 | 327 | 98 | 42.79% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VIR News
- 7 days ago - Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program - Business Wire
- 4 weeks ago - Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference - Business Wire
- 6 weeks ago - Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile - Business Wire
- 6 weeks ago - Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference - Business Wire
- 6 weeks ago - Vir Biotechnology, Inc. (VIR) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results - Business Wire
- 7 weeks ago - Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta - Business Wire
- 2 months ago - Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025 - Business Wire